Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There was a wall of 500,000 shares at .047, but it is gone now.
Absolutely nothing currently, which seems to be the problem. We were told that updates and progress were "imminent," but it's been crickets ever since. Peeps get frustrated and move on because they see other tickers moving.
Hopefully, we will hear something in the first week of September and not today or tomorrow before a long holiday weekend.
$NHYF
— Dave Yo (@daveyoslc) August 21, 2024
Looks like August 9th the name officially changed in Florida to#synbio #OTC #AI #Biomedical 💎 pic.twitter.com/5pHCbekrI0
1st and 2nd quarter reports were both amended and posted on otc markets yesterday, 8/13. I haven't had a chance to read through to see what was changed yet, but I have to assume this is more house cleaning before the next step.
It is really good news, but for now, no one seems to care. That's OK, Claude has been following a detailed road map and has been completing housekeeping tasks along the way. Now we just sit back and hope he follows through on his own words. From today's PR..
CEO and Managing Director Mr. Claudio Solitario said, "With the audits finalized and initial funding secured, we are poised to actively pursue initiatives that have the potential to significantly enhance shareholder value. The funding will allow the Company to formalize the relationships built over time and accelerate operational activities. This is an exciting period for the company with a new name, new funding, and new business opportunities on the horizon. I look forward to keeping shareholders regularly informed of progress.”
Unlocking Funds to Accelerate Operations
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Publicly-held Natural Harmony Foods Inc. (OTC: NHYF) is delighted to report the completion of its financial statement audits for the years 2022 and 2023. This accomplishment represents a significant advancement in the Company's corporate governance and will underpin its ongoing operations. It will also assist in removing its current shell status and lay the groundwork for its desired OTCQB listing.
The audits will also allow the Company to file S1 Registration Statements and access initial funding under its Promissory Note Agreement, which will accelerate the implementation of long-standing operational plans.
With a focus on revenue generation, the Company plans to allocate the initial funds primarily to the commercial launch of its nutraceutical products. A comprehensive marketing and sales strategy, including television and social media content, is in the advanced stages of planning. Initially, the Company’s focus will be on e-commerce in order to minimize costs and maximize market reach.
A portion of the initial capital will be allocated to advancing the due diligence phase of its clinical medical technologies, particularly its facial analysis technology for the objective identification of PTSD. Objective identification of mental health conditions has eluded professionals since the field's inception due to the subjective nature of psychological symptoms. An objective screening test will significantly aid in the early treatment of the condition.
The Company has registered Synbio International Inc with the State Department of Florida and awaits approval from FINRA for its new market ticker.
CEO and Managing Director Mr. Claudio Solitario said, "With the audits finalized and initial funding secured, we are poised to actively pursue initiatives that have the potential to significantly enhance shareholder value. The funding will allow the Company to formalize the relationships built over time and accelerate operational activities. This is an exciting period for the company with a new name, new funding, and new business opportunities on the horizon. I look forward to keeping shareholders regularly informed of progress.”
About Natural Harmony Foods, Inc.
Natural Harmony Foods Inc. (NHYF) aims to enhance patient outcomes and reduce healthcare costs by developing cutting-edge AI-powered methods to aid in the diagnosis of medical conditions. These methods enable early, accurate screening, contributing to quicker and more effective treatment. NHYF focuses on developing AI-based screening techniques for medical conditions, capitalizing on the growing role of AI in clinical practice. Additionally, NHYF acknowledges the thriving nutraceutical market's potential and plans to enter it for early revenue, benefiting from the growing emphasis on natural approaches and the demand for dietary supplements that offer potential health benefits beyond basic nutrition. The Company’s nutraceutical formulas are scientifically designed to nutritionally support the body’s inherent abilities to positively respond to health conditions and will address the needs of the great many people who are searching for natural remedies for their health and wellness. The demand for nutraceuticals continues to expand, creating a dynamic landscape for NHYF’s nutraceutical businesses to flourish.
Story Continues
news out, audits are complete for 2022 and 2023
OTC Markets lists this firm as the accountanting/auditing firm under service providers, so I'll assume they performed these audits. I did some reading on their website, and they seem to be legit, which I'm happy to see. No red flags for me yet and I hope it stays that way.
http://www.theaccellgroup.com/
Agree, and you make some very good points.
I also believe the name change is PR worthy, so I hope we hear something from the company soon. Perhaps they are waiting for a ticker change and/or audited financials before further communication?
agree, I have enough, but I'm tempted too
these 003s are going to look good for someone real soon, imo
3,733 shares traded today. Not much, but there's still a pulse. Hopefully, someone will revive this one.
I believe that an uplist is the plan as well. Here is an excerpt from the 9/19/23 PR...
Change of OTC Market Company Status
The transition of the Company's business to the development of medical technology and the commercialization of wellness products will require a higher level of corporate governance and transparency. To this end the Company is working towards a change of status from Pink to OTCQB.
I am in the good ole US of A and cannot buy this, only sell.
I follow some other CE stocks where buying is being done with Canadian brokerages only. The names mentioned are Scotia, RBC and Questrade.
165,000 shares traded today, so we still have a pulse.
I'm glad to see more progress being made and one more thing being crossed off the to-do list.
Meanwhile, I can confirm that we are not contemplating a reverse split, as it would adversely affect our funding facility. We are steadfastly committed to strategies that improve long-term growth and stability. Your continued patience and support are greatly valued.
— Claudio Solitario (@ClaudeSolitario) June 7, 2024
These posts are the first of many that will keep you informed of our progress in the upcoming weeks.
— Claudio Solitario (@ClaudeSolitario) June 7, 2024
To our valued shareholders & stakeholders, the highly credentialed & devoted team at $NHYF have been working quietly and diligently towards certain critical milestones, which are now imminent.
— Claudio Solitario (@ClaudeSolitario) June 7, 2024
Agree.
Patently waiting for the day when peeps are chasing this one (hopefully).
I think some sold to chase GME, AMC and other short meme stocks.
We have to be close to some sort of update.
Regarding the shell status change in the amended report, I assume that it's just a housekeeping issue that needed to be corrected when the lawyers read everything over.
At 12/31/23, I believe she'll status would be correct based on the following.
"In particular, a shell company is defined as any issuer, that has: (i) no or nominal operations; and (ii) either no or nominal assets or assets consisting solely of cash or cash equivalents or assets consisting of any amount of cash and cash equivalents and nominal other assets. A company will not be considered a shell simply because it is a start-up or has limited operating history. In order to have a reasonable basis for its determination, a broker-dealer or OTC Markets can review public filings, financial statements, business descriptions, etc."
https://securities-law-blog.com/2023/02/28/the-211-rules-and-shell-companies/#:~:text=OTC%20Markets%20has%20also%20designated,via%20the%20alternative%20disclosure%20system.
Address what exactly JB? I feel like they already addressed any issues with the 2023 filing?
Just noticed an amended 2023 report and attorney letter with respect to current information were filed on 4/26.
The only change I can see in the filing is changing the shell status from no to yes.
https://www.otcmarkets.com/stock/NHYF/disclosure
JDT Legal/Jeff Turner are serving as legal counsel.
I was under the impression that the only shares that were canceled were those of holders could not be reached, but I could be off and my bad if so. We should get clarity in the 2024 Q1 filing.
What is surprising is the total lack of interest at this point. Maybe once they start producing revenues/profit, this will get noticed.
In the old OTC days, these kinds of developments would have at least produced some volume and interest.
Interesting that Sam Dewar still owns 35.5 million shares. He is the original founder/owner of NHYf with a pretty impressive resume himself.
I wonder if he'll have any role moving forward or will he sell all when the price is right?
https://www.linkedin.com/in/sam-dewar-6ab115a
The last piece of housecleaning is now complete. Now we sit here at the starting line and watch the story unfold.
PR soon and expect a name and symbol change will come shortly.
Nice. Financials and PR next.
I like this part from the official PR
Mr. Randy Rivera, Director of Global Corporate Finance, said:
"The investment in NHYF is a logical step in GCF's strategy to invest in companies at the forefront of AI-powered medical technology. Companies with unique strategic investments in the AI medtech space have the potential to develop significant value over the next two to five years and we look forward to a long and productive association with NHYF".
Nice post. Global Corporate Finance, LLC is the investor you mention. Here is the official PR (for anyone new here).
Natural Harmony Foods Inc. Signs US$5,000,000 Equity Facility to Fund GrowthPress Release | 11/16/2023
NEW YORK, NY / ACCESSWIRE / November 16, 2023 / Publicly-held Natural Harmony Foods, Inc. (OTC PINK:NHYF) ("the Company") is pleased to announce today that it has entered into a Securities Purchase and Subscription Agreement with Global Corporate Finance Inc. ("GCF"), an esteemed private family office located in New York City, to provide working capital that will underpin the Company's growth.
?
The Securities Purchase and Subscription Agreement will enable the Company to draw up to US$5,000,000 at its discretion over a period of 30 months. In return for each drawdown, the Company will issue common stock at discount of 9% to the Company's average daily volume weighted stock price during the five (5) consecutive trading days immediately preceding the date of the Company's drawdown request. The cost of securing the facility is considered to be appropriate for the transaction.
The funds will be used to launch the first of the Company's nutraceutical products; the acquisition and development (subject to due diligence) of AI-based intellectual property; and general working capital, including up-listing the Company to OTCQB status as quickly as possible.
Mr. Randy Rivera, Director of Global Corporate Finance, said:
"The investment in NHYF is a logical step in GCF's strategy to invest in companies at the forefront of AI-powered medical technology. Companies with unique strategic investments in the AI medtech space have the potential to develop significant value over the next two to five years and we look forward to a long and productive association with NHYF".
Mr. Claudio Solitario, CEO of Natural Harmony Foods Inc. adds:
"We are delighted to be partnering with Global Corporate Finance Inc. and are very grateful for their financial support. The facility will provide the capital required to execute our growth plans and build shareholder value. Our collaboration with GCF is a testament to our shared vision for innovation and growth. The capital will serve as a dynamic catalyst to propel our strategic initiatives forward. We too look forward to a long and productive working relationship with GCF".
For media and Investor Relations inquiries, please contact: ir@nhyf.net
Thanks for the clarification on the filing dates, etc. Hopefully good times ahead for all those who have been patient with this one.
No worries here, we didn't come all this way to not file a 2023 report before we even get started.
I was just letting him know I'd expect to see something filed and possibly a PR by 4/14, which is a Sunday, so maybe by Friday the 12th.
A notice of late filing was posted yesterday.
https://www.otcmarkets.com/stock/NHYF/disclosure
This filing gives them until 4/14/24 to file the 2023 annual report. I bet we get a PR to go along with it.
Nice PR, straight facts, no fluff, no BS. I like it, but most P&D chasers won't.
This part caught my eye..
"I am pleased to announce the successful conclusion of my role as custodian of NHYF. I have instructed my attorney to formally discharge the custodianship."
If my assumption is correct, there can be no R/S for one year from this date since the custodianship is now concluded, effective 3/26/24. No R/S can occur before 3/26/25 per terms of the original agreement.
Any legal minds in this that can confirm or deny?
Agree...PR out today re: share cancelation
Reposting from September..
Yesterday's PR mentioned a partnership with a Dr. Robert Lawrence. I'm not 100% sure if this is him but if it is, he's got an impressive resume. This team is going to be the real deal.
https://www.egh1.com/resdev.html
Research & Development
In 1991, Dr. Robert Lawrence, PhD. Biomedical Engineering, PhD. Nuclear Physics, MS Microbiology, MS Computer Science and world-renowned Polymer Physicist, developed an oral delivery system for Growth Hormone (GH). Dr. Lawrence was later named Chief Science Officer of the $2.8 million dollar project initiated by Bushard Pharmaceuticals. He developed a unique vegetable-based enzyme polymer, which allowed large molecule such as Growth Hormone to be absorbed via the oral mucosa. Between 1991 and 1997, thousands of scientific studies were conducted in five major U.S. cities by Bushard's medical team under the thorough supervision of Dr. Lawrence. These studies verified the validity of this new and revolutionary oral application of GH.
Tested were people between the ages of 31 and 89 with average to fair health conditions. Protocols for the studies included: fasting from all nutritional vitamins and supplements two weeks prior to study, IRB Study Protocols, IGF-1 (insulin-like growth factor, type 1), HDL and LDL levels prior to and during all testing and S.M.A.C. test (liver enzymes and kidney enzymes). Levels of the above tests were conducted every 30 days to determine the efficacy of the new oral spray application.
The results were astounding -- not only were there no side effects, but test subjects had an average increase in their IGF-1 levels of 30% every 30 days. In 90 days, most of the test subjects had doubled their IGF-1 levels, which represented a measurable improvement in biological age as effective -- or in some cases, more effective -- as had been found with patients taking injections of Growth Hormone! Cholesterol levels were diminished in over 80% of patients by an average of 14.8%, and triglyceride levels also diminished by 31%. Noted were increases in mental stability, lean muscle mass, energy, libido, skin rejuvenation, and reacquired hair color and density. Also noted were reductions in excess weight, blood pressure and blood sugar.
When the project concluded in 1997, Bushard Pharmaceuticals, due to failed markets at the time, closed its doors permanently. In the following year, interested opportunists came out with oral spray Growth Hormone products, substandard to the original formulation. These manufacturers of oral GH used cheap plastic, petroleum-based polymers -- costing only a few dollars per gallon and of questionable health consequences. Dr. Lawrence was disappointed with the mockery that had been bestowed upon his discoveries and set out to recreate the original formulation he developed as a totally vegetarian, safe & effective polymer. The original polymer created by Dr. Lawrence had a purchase value of over $62,000 per gallon and was backed up by seven years of successful clinical studies. He began to produce the product for his family and friends, and shortly thereafter, he formulated Human Growth Hormone Replacement Therapy GH1 Oral Spray Growth Hormone.
EGH-1 has been tested extensively with many methods and modalities of today's modern science, most notably the VEGA Machine from Germany, which is a very refined form of electro-dermal, precision instrumentation used in medical practices today. The VEGA Machine measures a person's positive or negative reaction to a given substance. EGH-1 was recently featured as an exemplary product at the International VEGA Symposium in Grieshaber, Germany.
There are now over 25 documented health benefits associated with EGH-1. Testimonials from all over the world acknowledge a wide variety of physiological, emotional and mental improvements. Consistent use of EGH-1 stimulates a very natural process in the human system whereby one's own pituitary gland resumes secretion of Growth Hormone at levels which occurred during youth, thereby regulating the entire endocrine system, including modulation of hormones, blood pressure and cholesterol levels.
JB,
I'm reposting this press release from September as a reminder to all of their plan to develop and deliver in the AI Healthcare solutions space.
It's a good read, and if you look at some of the names they will be partnering with, there appears to be some serious brilliant minds coming together here.
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / Publicly-held Natural Harmony Foods, Inc. (OTC PINK:NHYF) (the Company) announces that following the change of control to Mr. Claudio Solitario, announced recently, the Company is now on a transformative path, signaling a compelling strategic direction. The Company's transition under Claudio's leadership signifies a dynamic shift towards innovation and growth, underpinned by his extensive knowledge and experience in medical technology and intellectual property development and commercialization.
?
Mr. Claudio Solitario
The Power of Artificial Intelligence Solutions in Healthcare
Central to NHYF's transformation is its commitment to harness the power of Artificial Intelligence (AI) in healthcare. AI-driven medical technology is set to revolutionize the field, promising faster, more accurate diagnoses; personalized treatment plans, and improved patient outcomes. AI's potential to transform the medical field is undeniable, offering promise of more efficient and effective healthcare for all. The Company will be at the forefront of this exciting advancement in medical technology focusing on the development of AI-powered screening methods and to this end, is forming strategic partnerships in an effort to co-develop the following:
Life-Saving Innovation: AI-based intellectual property for the fast and early identification of life threatening pulmonary embolisms using CAT scan detection software. A pulmonary embolism is a medical emergency; it may be fatal causing death. Pulmonary embolism affects around 900,000 people in the U.S. every year1. The AI-powered technology aims to improve the radiologic processing time and reading performance during emergency evaluations.
Facial Analysis to objectively screen for PTSD: AI-based facial analysis technology to objectively screen for post-traumatic stress disorder. The technology will analyze and interpret facial data, the result of which will be seen immediately by the user - with an option of sending it to their medical practitioner. This innovative approach will empower individuals and their healthcare providers to proactively manage mental health. The incidence of mental illness in the USA is well known; and the cost is estimated at $300Billion annually2. A quick and objective assessment of PTSD is required by patients and healthcare professionals alike.
Evolution in Evaluation and Treatment of Pain Management: A breakthrough new AI program (Chatbot) to simulate conversation with individuals suffering from chronic pain. The program will be designed to immediately address the pain sufferer's acute and chronic pain and provide viable options to consider as they search for a medical personnel who has the appropriate expertise. It will also create a written dialogue that can be reviewed by medical practitioners and may become an integral part of the pain sufferer's comprehensive pain management plan. This breakthrough AI-based technology, under the guidance of Dr. Robert Lawrence, a retired Neurologist with PhDs in Nuclear Physics and Biomedical Engineering, along with MS Degrees in Computer Science and Pharmacology, will be a game-changer for the over 51 million Americans (over 20% of the adult population3) affected by chronic pain.
AI's capacity to process vast volumes of data positions it as a pivotal tool in the aid to diagnosis across diverse medical domains. By leveraging machine learning algorithms, AI can analyze vast amounts of medical data, from patient records to medical images and by identifying patterns and insights that may escape human detection. This capability can lead to earlier and more accurate diagnoses, personalized treatment plans and improved patient outcomes. Importantly, AI-powered technologies can also enhance patient engagement, provide 24/7 support and help individuals manage their health proactively.
Innovative Nutritional Wellness Solutions for Early Revenue Opportunity
NHYF's vision extends beyond AI, encompassing innovative nutraceutical solutions. The company is poised to launch an anti-anxiety product - the first of its nutritional supplements that can be added to medical protocols for the long-term management of anxiety. The formula was scientifically designed as an active dietary supplement to nutritionally support the body's inherent abilities to positively respond to stressful conditions. It will address the needs of the great many people who are searching for natural supplements that may help address symptoms associated with their anxiety. David Anderson MD, a highly respected U.S. medical school-associated research physician will ensure all claims and presentations are maximized whilst complying with Regulatory Agency Guidelines.
The market for nutraceuticals in the USA has been experiencing robust growth, driven by increasing consumer awareness of the link between diet, health, and wellness. With a growing emphasis on preventive healthcare, the demand for dietary supplements and functional foods that offer potential health benefits beyond basic nutrition continues to expand, creating a dynamic landscape for the Company's nutraceutical businesses to flourish.
Change of OTC Market Company Status
The transition of the Company's business to the development of medical technology and the commercialization of wellness products will require a higher level of corporate governance and transparency. To this end the Company is working towards a change of status from Pink to OTCQB.
Speaking on behalf of the Company, newly appointed CEO, Mr. Claudio Solitario said: " We are excited to embark on this transformative journey. AI is fast becoming an important tool in the quest for faster and more accurate diagnoses. Our mission is to leverage AI to enhance health outcomes and reduce healthcare costs. We also look forward to launching our pioneering anti-anxiety formula, the first of our nutraceutical products. The market demand for nutraceuticals is significant and growing, representing an early revenue opportunity for the Company. The path ahead is exciting and we look forward to keeping shareholders abreast of progress in the coming weeks and months".
1 https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism
2 https://www.nami.org/Press-Media/In-The-News/2021/2020-devastated-US-mental-health-%E2%80%94-healing-must-be-a-priority
3 https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm#contribAff
For media and Investor Relations inquiries, please contact: ir@nhyf.net
The official website at www.nhyf.net
Updated share structure updated on OTC markets. I think we see a PR today or early next week to address to the cancelation and formal change of control.
NHYF SECURITY DETAILS
Share Structure
Market Cap ?
1,547,483
03/21/2024
Authorized Shares
600,000,000
03/21/2024
Outstanding Shares
309,496,511
03/21/2024
Restricted
33,240,000
03/21/2024
Unrestricted
276,256,511
03/21/2024
Held at DTC
273,334,274
03/21/2024
Float
276,256,511
06/15/2023
Par Value
0.001
Thanks for reposting this, I was thinking the same.
Here is another tweet that any potential new investors should be aware of.
$NHYF I have agreed to stay on as a consultant if needed or just be a resource as need arises. Synergy is keeping 1 Pref B share which is why I provided a lower price. I have a vested interest in the company successhttps://t.co/DDfOSnirL7
— Synergy Management (@synergymgtgroup) August 10, 2023
Excellent, thanks.